[Current status of treatment of refractory ascites in patients with liver cirrhosis].
Zhonghua Gan Zang Bing Za Zhi
; 24(10): 721-723, 2016 Oct 20.
Article
in Zh
| MEDLINE
| ID: mdl-27938554
ABSTRACT
Ascites is a common clinical manifestation of cirrhotic portal hypertension, and about 60%-80% of cirrhotic patients develop the symptom of ascites within 10 years. Once ascites occurs, the 5-year survival rate is reduced from 80% to 50%. With the progression of liver diseases, approximately 5%-10% of patients with ascites develop refractory ascites, and the median survival time is only 6-12 months. This article reviews the definition and diagnosis of refractory ascites, evaluation of prognostic factors, and treatment regimens, including large-volume paracentesis combined with protein supplementation, transjugular intrahepatic portosystemic shunt, and liver transplantation.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Ascites
/
Paracentesis
/
Portasystemic Shunt, Transjugular Intrahepatic
/
Liver Cirrhosis
Type of study:
Etiology_studies
/
Prognostic_studies
Limits:
Humans
Language:
Zh
Journal:
Zhonghua Gan Zang Bing Za Zhi
Journal subject:
GASTROENTEROLOGIA
Year:
2016
Document type:
Article
Affiliation country:
China
Publication country:
CHINA
/
CN
/
REPUBLIC OF CHINA